RSV Vaccination: Essential Protection for Older Adults and At-Risk Groups
Respiratory diseases can be dangerous for older people and those with previous illnesses. The STIKO recommends the RSV vaccination for these groups of people.
Understanding RSV and Its Impact
Berlin – With the arrival of the wet and cold season, the risk of infectious diseases, notably the respiratory syncytial virus (RSV), increases significantly. RSV is a common virus that can cause severe respiratory symptoms, particularly among vulnerable populations. The Standing Vaccination Commission (STIKO) has recently advised that all adults aged 75 and over, as well as those at increased risk aged 60 and over, receive an RSV vaccination. As of October 2024, health insurance companies are covering the RSV vaccination costs for these groups.
RSV Vaccination: Health Insurance Benefit
According to STIKO, individuals over 75 and those 60 or older with heightened health risks should receive a single vaccination ahead of the RSV season, which typically spans from October to March. The recommended vaccines include:
- Arexvy
- Abrysvo
Target Population for Vaccination
The main goal of the RSV vaccination is to mitigate respiratory infections caused by RSV in those aged 75 and older and in individuals 60 and older who face a significantly increased risk of severe infection. High-risk populations include:
- People with chronic respiratory diseases
- Individuals with cardiovascular and kidney diseases
- Patients with certain types of cancer
- Individuals with chronic neurological and neuromuscular disorders
- Diabetics with complications
- Persons with severe immune deficiencies
This recommendation also extends to 60-year-olds residing in care facilities.
Infant Protection: STIKO’s Recommendations for Newborns
Infants represent another group at high risk for RSV infection due to their sensitive and underdeveloped lungs. This vulnerability allows the virus to spread rapidly through their respiratory systems, potentially causing severe symptoms. To combat this, STIKO recommends passive immunization for newborns and infants through a single injection of the monoclonal antibody nirsevimab (Beyfortus; Sanofi) during the first RSV season. This intervention is crucial in protecting young children from the virus.
The Importance of Early Vaccination
To best protect against RSV, it is essential to administer the vaccination in late summer or autumn. This timing ensures that individuals are immunized before the onset of the RSV season.
Benefits of RSV Vaccination
| Benefit | Description |
|---|---|
| Reduces Hospitalization | Vaccination lowers the likelihood of severe complications requiring hospital care. |
| Protects Vulnerable Groups | It specifically protects those most susceptible, including the elderly and infants. |
| Cost-effective Care | Coverage by health insurance reduces out-of-pocket costs for patients. |
Practical Tips for Vaccination
- Consult Your Doctor: Speak with your healthcare provider to assess your eligibility for the RSV vaccination.
- Know Your Insurance Benefits: Verify with your health insurance regarding coverage for the RSV vaccination.
- Plan Ahead: Schedule your vaccination in late summer or autumn to ensure protection before the RSV season starts.
- Keep Records: Maintain a record of your vaccination for future reference and healthcare needs.
Conclusion
The recommendations by STIKO reflect the importance of vaccination in preventing severe respiratory illness due to RSV, particularly among older adults and vulnerable infants. By understanding and taking action, individuals can protect themselves and their loved ones during the RSV season.
